Brief: Organicell Announces FDA Approval Of Ind Application For The Treatment Of Sars Due To Covid-19
05/05/2020 14:06
May 5 (Reuters) - Organicell Regenerative Medicine Inc
BPSR.PK :
* ORGANICELL ANNOUNCES FDA APPROVAL OF IND APPLICATION FOR
THE
TREATMENT OF SARS DUE TO COVID-19
Source text for Eikon: ID:nGNX9PP6RZ
Further company coverage: BPSR.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zeo Scientifix
See all newsBrief: Organicell Regenerative Says Zofin Therapy Approved By Pakistani Regulators To Be Used For A Covid-19 Patient On Compassionate Grounds
Brief: Organicell Begins Up-Listing Process On Nasdaq
Brief: Organicell Announces Positive Results Of Initial Covid-19 Zofin™ Patient Trial In India And Trial Expansion
Brief: Organicell Completes Enrollment For Its Expanded Access Trial To Treat Covid-19 Patients With Zofin™
Brief: Organicell Announces FDA Approval Of IND Application For Use Of Zofin In The Treatment Of Chronic Obstructive Pulmonary Disease